In:
Pediatric Transplantation, Wiley, Vol. 26, No. 4 ( 2022-06)
Kurzfassung:
Liver biopsy is the gold standard for hepatic fibrosis staging, but it is invasive and has potential severe complications. We aimed to determine the diagnostic performance of 2D‐SWE and serum markers to predict significant hepatic graft fibrosis (≥F2) in pediatric liver‐inclusive transplant recipients. Methods This prospective, cross‐sectional pilot study included children younger than 19 years who had received a LT or LSBT and underwent a liver biopsy performed for clinical indications. LS was measured using 2D‐SWE. The AUROC was calculated to evaluate the diagnostic performance of 2D‐SWE and biomarkers (AST/ALT ratio, APRI, FIB4) for predicting significant fibrosis. Results Twenty‐two children (13 males, 8 LSBT) were included. Eighteen (81.8%) children received a whole liver graft. Thirteen (59.1%) patients had hepatic fibrosis (≥F1) and four (18.2%) had significant fibrosis. The AUROCs of AST/ALT ratio, APRI, and FIB4 for predicting significant hepatic graft fibrosis were 0.71 ( p = .29), 0.85 ( p = .0001), and 0.76 ( p = .03), respectively. When FIB4 was calculated using the hepatic graft's age, its AUROC improved to 0.85 ( p 〈 .0001). The AUROC of 2D‐SWE for predicting significant hepatic graft fibrosis was 0.80 ( p = .046). When 2D‐SWE was combined with APRI or FIB4, its AUROC improved to 0.82 ( p = .08) and 0.87 ( p = .002), respectively. Conclusions APRI and FIB4 can accurately predict significant hepatic graft fibrosis. 2D‐SWE may serve as a valuable adjunct tool to detect significant graft fibrosis, especially when combined with these serum markers.
Materialart:
Online-Ressource
ISSN:
1397-3142
,
1399-3046
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2022
ZDB Id:
2008614-3
